1.Adverse events following immunisation with the first dose of sputnik V among Iranian health care providers
Reza Jafarzadeh ESFEHANI ; Masood ZAHMATKESH ; Reza GOLDOZIAN ; Javad FARKHONDE ; Ehsan JARIPOUR ; Asghar HATAMI ; Hamid Reza BIDKHORI ; Seyyed Khosro SHAMSIAN ; Seyyed AliAkbar SHAMSIAN ; Faezeh MOJAHEDI
Clinical and Experimental Vaccine Research 2023;12(1):25-31
Purpose:
Since late 2019, the novel coronavirus disease has been a global concern, and alongside preventive strategies, including social distancing and personal hygiene, vaccination is now the primary hope for controlling the pandemic. Sputnik V is an adenovirus vector vaccine used against coronavirus disease 2019 (COVID-19) among Iranian health care providers, and there is a lack of information regarding the Adverse Events Following Immunisation (AEFI) by Sputnik V among the Iranian population. The present study aimed to evaluate AEFI by Sputnik V vaccine among Iranian population.
Materials and Methods:
Every member of the Islamic Republic of Iran Medical Council received their first dose of the Sputnik V vaccine in Mashhad (Iran) and was referred to receive their second dose enrolled in the present study and asked to fill an English language checklist asking about development of any AEFI following immunization with the first dose of Sputnik V vaccine.
Results:
A total number of 1,347 with a mean±standard deviation age of 56.2±9.6 years filled the checklist. Most of the participants were male (838 [62.2%]). The present study demonstrated that immunization with the first dose of Sputnik V results in at least one AEFI in 32.8% of the Iranian medical council members. Most of the AEFI was related to musculoskeletal symptoms, including myalgia. By considering the age of 55 years as a cut-off point, individuals younger than 55 had a higher rate of AEFI (41.3% vs. 22.5%, p=0.0001). Male gender, use of analgesics, beta-blockers, and previous COVID-19 infection have a lower chance of developing AEFI (p<0.05).
Conclusion
The present study demonstrated that most of the AEFI was related to musculoskeletal symptoms, including myalgia, and older individuals, male gender and those receiving analgesics and beta-blockers were less likely to develop AEFI following immunization with the first dose of Sputnik V.
2.Goiter Frequency Is More Strongly Associated with Gastric Adenocarcinoma than Urine Iodine Level.
Mohammad TABAEIZADEH ; Vahid HAGHPANAH ; Abbasali KESHTKAR ; Shahryar SEMNANI ; Gholamreza ROSHANDEL ; Khadijeh ADABI ; Ramin HESHMAT ; Davood ROHANI ; Alireza KIA ; Ehsan HATAMI ; Ataollah JAHANGIRRAD ; Ramin NABIZADEH ; Bagher LARIJANI
Journal of Gastric Cancer 2013;13(2):106-110
PURPOSE: We designed our study to evaluate the hypothesis that gastric cancer is correlated with iodine deficiency or thyroid dysfunction. MATERIALS AND METHODS: We investigated the total body iodine reserve, thyroid function status and autoimmune disorder in 40 recently diagnosed gastric adenocarcinoma cases versus 80 healthy controls. The participants came from a region with high gastric cancer rate but sufficient iodine supply due to salt iodination. The investigation included urine iodine level, thyroid gland clinical and ultrasonographic examination, and thyroid function tests. RESULTS: Goiter was detected more frequently in the case group (P=0.001); such a finding, however, was not true for lower than normal urine iodine levels. The free T3 mean level was significantly lower in the case group compared to the control group (P=0.005). CONCLUSIONS: The higher prevalence of goiter rather than low levels of urinary iodine in gastric adenocarcinoma cases suggests that goiter, perhaps due to protracted but currently adjusted iodine deficiency, is more likely to be associated with gastric adenocarcinoma compared to the existing iodine deficiency itself.
Adenocarcinoma
;
Autoimmune Diseases
;
Goiter
;
Halogenation
;
Iodine
;
Porphyrins
;
Prevalence
;
Stomach Neoplasms
;
Thyroid Function Tests
;
Thyroid Gland